BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morgensztern D, Govindan R. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology. Clin Lung Cancer. 2008;9 Suppl 2:S57-S61. [PMID: 21885000 DOI: 10.3816/clc.2008.s.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Yang L, Chen CJ, Guo XL, Wu XC, Lv BJ, Wang HL, Guo Z, Zhao XY. Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis. J Neurooncol 2018;137:49-56. [PMID: 29170906 DOI: 10.1007/s11060-017-2693-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
2 Stefanou D, Stamatopoulou S, Sakellaropoulou A, Akakios G, Gkiaouraki M, Gkeka D, Prevezanou M, Ardavanis A. Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases. Oncol Lett 2016;12:4635-42. [PMID: 28101218 DOI: 10.3892/ol.2016.5268] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
3 Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, Setoyama R, Toyoda T. Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases. World J Gastroenterol 2011; 17(39): 4440-4444 [PMID: 22110272 DOI: 10.3748/wjg.v17.i39.4440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]